Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. BioCryst Pharmaceuticals Inc. shares valued at $1,038,000 were sold by Stonehouse Jon P on Feb 01. At $10.38 per share, Stonehouse Jon P sold 100,000 shares. The insider’s holdings dropped to 1,008,739 shares worth approximately $8.91 million following the completion of this transaction.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Also, Stonehouse Jon P sold 14,100 shares, netting a total of over 153,690 in proceeds. Following the sale of shares at $10.90 each, the insider now holds 887,730 shares.
Before that, Gayer Charles K had sold 6,100 shares from its account. In a trade valued at $66,490, the Chief Commercial Officer traded BioCryst Pharmaceuticals Inc. shares for $10.90 each. Upon closing the transaction, the insider’s holdings decreased to 6,100 shares, worth approximately $1.87 million.
As published in a research note from Needham on February 22, 2023, BioCryst Pharmaceuticals Inc. [BCRX] has been rated up from a Hold to a Buy and the price target has been revised to $14. This represents a 36.93% premium over Wednesday’s closing price. Analysts at Evercore ISI upgraded the stock from ‘”an In-line”‘ to ‘”an Outperform”‘ outlook in a report released in early November. As of August 05, 2022, Oppenheimer has decreased its “an Outperform” rating to a “Perform” for BCRX. Earlier on August 05, 2022, Evercore ISI downgraded its rating. Their new recommendation was “an In-line” for BCRX stock which previously was a “an Outperform”.
Analyzing BCRX Stock Performance
On Wednesday, BioCryst Pharmaceuticals Inc. [NASDAQ: BCRX] plunged -0.23% to $8.83. The stock’s lowest price that day was $8.635, but it reached a high of $8.99 in the same session. During the last five days, there has been a drop of approximately -9.62%. Over the course of the year, BioCryst Pharmaceuticals Inc. shares have dropped approximately -23.08%. Shares of the company reached a 52-week high of $12.07 on 01/06/23 and a 52-week low of $8.12 on 02/21/23. A 50-day SMA is recorded $10.45, while a 200-day SMA reached $11.70. Nevertheless, trading volume fell to 3.44 million shares from 3.54 million shares the previous day.
Support And Resistance Levels for BioCryst Pharmaceuticals Inc. (BCRX)
According to the 24-hour chart, there is a support level at 8.65, which, if violated, would cause prices to drop to 8.46. In the upper region, resistance lies at 9.00. The next price resistance is at 9.17. RSI (Relative Strength Index) is 35.91 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.74, which suggests the price will decrease in the coming days. Percent R is at 70.44%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.
Is BioCryst Pharmaceuticals Inc. subject to short interest?
Stocks of BioCryst Pharmaceuticals Inc. saw a sharp steep in short interest on Jan 30, 2023 dropping by -0.56 million shares to 26.68 million. Data from Yahoo Finance shows that the short interest on Dec 29, 2022 was 27.24 million shares. A decline of -2.1% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 8.54 of the overall float, the days-to-cover ratio (short ratio) decline to 8.54.
Which companies own the most shares of BioCryst Pharmaceuticals Inc. (BCRX)?
According to The Vanguard Group, Inc. filings, the company currently owns 13,754,831 shares, which is about 7.38% of the total BCRX shares outstanding. The investor’s shares have appreciated by 349,913 from its previous 13-F filing of 13404918.0 shares. With the completion of the buy transaction, BlackRock Fund Advisors’s stake is now worth $137,707,905. A total of 0 shares of BioCryst Pharmaceuticals Inc. were bought by Avoro Capital Advisor LLC during the quarter, and 1,331,109 were bought by Fidelity Management & Research Co. In its current portfolio, Pictet Asset Management SA holds 5,285,348 shares valued at $55.76 million.
In terms of BioCryst Pharmaceuticals Inc. share price expectations, FactSet research, analysts set an average price target of $15.45 in the next 12 months, up nearly 46.89% from the previous closing price of $8.85. Analysts anticipate BioCryst Pharmaceuticals Inc. stock to reach $30.00 by 2023, with the lowest price target being $8.00. On April 18, 2022, Barclays assigned a price target of “an Equal weight” to the stock and downgraded coverage with a $13.